AirNexis Therapeutics, Inc.

AirNexis Therapeutics is a biopharmaceutical company based in the US, dedicated to developing innovative therapies that address unmet medical needs in oncology and autoimmune disorders. Founded in 2025 and headquartered in Palo Alto, US, AirNexis Therapeutics focuses on creating advanced biologics and small molecule therapies. The company has successfully secured funding through a SERIES A round in January 2026, raising USD 200 mn led by Frazier Healthcare Partners. Founders' history is not available.

The total amount raised to date is USD 200 mn with a current valuation of USD 311. 64 mn. AirNexis Therapeutics specializes in developing innovative therapeutic solutions targeting unmet medical needs, especially in oncology and autoimmune disorders. Their offerings include advanced biologics and small molecule therapies, utilizing techniques like monoclonal antibody production and gene editing technologies.

The company's products are tailored for healthcare providers, hospitals, and specialized clinics across North America and Europe, focusing on improving patient outcomes for both adult and pediatric populations. AirNexis Therapeutics generates revenue through direct sales and strategic partnerships with healthcare organizations. Their B2B model allows products to be integrated into treatment protocols of healthcare providers and institutions. Revenue structures include one-time purchases and long-term supply agreements, reflecting the advanced nature of their therapies and competitive pricing based on therapeutic complexity.

In January 2026, AirNexis Therapeutics raised USD 200 mn in SERIES A funding to advance global clinical trials for its dual phosphodiesterase three and four inhibitor, AN01. The company aims to support regulatory activities for treating chronic obstructive pulmonary disease. Future plans include launching new products and expanding into new markets, although specific geographical targets and timelines were not disclosed.